in page functions

21 December 2011

2010 Work Plan Report

The 2010 Work Plan Report highlights the 2010 progress under each output of the 2007-2010 work plan.

22 August 2011

Manufacturers FAQs

Frequently asked questions about Advance Market Commitments for vaccines for manufacturers.

01 July 2011

IFFI evaluation: IFFIm donor response

Donors feel that the report presents valuable information about the goal effectiveness, costs effectiveness, and impacts in terms of lives saved by IFFIm. The evaluation shows, while highlighting constraints (size), lost opportunities (frontloading too early) and potential challenges (sustainability), that IFFIm has so far achieved impacts beyond those specifically targeted for immunisation.

01 July 2011

IFFIm evaluation: key messages

The International Financing Facility for Immunisation (IFFIm) concept is proven. IFFIm has allowed donor countries to make binding long-term commitments and convert these future cash flows into immediately available funds through the financial markets at a cost very close to that achieved by the World Bank. 

01 July 2011

IFFIm evaluation: executive summary

This evaluation was commissioned by the GAVI Secretariat, on behalf of the IFFIm Board, to assess the extent to which the IFFIm has been an effective financing mechanism to raise money for immunisation and health systems in GAVI eligible countries.

01 July 2011

IFFIm evaluation: The World Bank response

The World Bank has reviewed an evaluation report of the International Finance Facility for Immunisation (IFFIm) prepared by HLSP and dated June 2011. The World Bank provides services to IFFIm under the Treasury Management Agreement and this report substantially reviews those activities in the context of IFFIm’s overall performance as a financing vehicle.

01 July 2011

IFFIm evaluation: IFFIm Board response

This paper provides a response to the IFFIm Evaluation by the IFFIm Board of Directors. 

28 June 2011

IFFIm evaluation: GAVI Secretariat response

GAVI Secretariat response to IFFIm evaluation which assessed both IFFIm’s efficacy as a financing mechanism, as well as the extent to which IFFIm has contributed to enhancing GAVI’s impact on immunisation and health.

21 June 2011

IFFIm evaluation: full report

The IFFIm evaluation assesses the extent to which IFFIm is an effective and efficient instrument to attract long-term, predictable donor funds and to frontload money to finance GAVI Alliance support for immunisation and health systems.

16 June 2011

Remaining AMC offer amount: June 2011

The official formal notification of the remaining AMC Offer Amount.

20 April 2011

IFFIm evaluation: annexes

1 . A. 21 February 2011 Evaluation of the International Finance Facility for Immunisation (IFFIm) ANNEXES April 2011 HLSP, Sea Containers House, 20 Upper Ground, London SE1 9LZ, United Kingdom T +44 (0)20 7803 4545 F +44 (0)20 7803 4502, W Evaluation of the International Finance Facility for Immunisation (

11 March 2011

Pneumo SDF version 3.0 – published on 11 March 2011

This version 3.0 is issued in accordance with the AVI Forecasting Standard Operating Procedure. The forecast captures all AMC‐eligible demand including countries that: introduce with GAVI support, graduate from GAVI support, and are fully self-financed.

09 March 2011

AMC Legal Agreements: detailed list of modifications

List of modifications to the AMC legal agreements.

07 March 2011

AMC deed of amendment and restatement

AMC deed of amendment and restatement relating to the Advance Market Commitment for pneumococcal vaccines offer agreement, IAC Charter & bylaws and procedures memorandum orginally dated 12 June 2009.

07 March 2011

Revised AMC procedures memorandum

This Procedures Memorandum describes the procedures that would be applicable to any AMC.

07 March 2011

Revised AMC offer agreement


Offer agreement relating to the Advance Market Commitment for pneumococcal vaccines.

03 February 2011

Second GAVI Evaluation 2006-2010

This evaluation seeks to answer two high-level questions: to what extent has the GAVI Alliance met its four Strategic Goals (SGs); and to what extent has the GAVI Alliance added value at the global and country levels, over and above what would have been accomplished without the Alliance?

01 February 2011

Kenya : pneumonia and pneumococcal disease

Childhood pneumonia is a major public health issue in Kenya; it is the second leading cause of death among children under five. Thanks to the AMC, two vaccines (PCV10 and PCV13) against pneumococcal disease have been approved so far for introduction in GAVI-eligible countries.


close icon

modal window here